Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2023-06-05

FDA Approved: PREVYMIS — Supplemental Application (Merck Sharp & Dohme LLC)

View source ↗

Summary

FDA approved a supplemental application for PREVYMIS (letermovir) submitted by Merck, resulting in changes to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • PREVYMIS (letermovir)

Snippet

SUPPL AP for PREVYMIS (LETERMOVIR)